SynAct Pharma announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate
November 1, 2023
SynAct Pharma AB carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million
SynAct Pharma announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP
BioStock: Positive subgroup data in SynAct Pharmas’s EXPAND study
Biotech SynAct Pharma has unveiled additional data from its EXPAND phase II clinical trial with resomelagon for rheumatoid arthritis. The new findings indicate consistent responsiveness to the drug candidate in a sub-population of patients with c-reactive protein level exceeding 3 mg/L, which is an indicative for active systemic inflammation. These encouraging findings are important for further development of resomelagon, according to the company’s CSO Thomas Jonassen in an interview.
CEO Torbjørn Bjerke comments on the recent development – November 24, 2023
Torbjørn Bjerke comments on the additional data from the Expand clinical trial – September 13, 2023
Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
Resomelagon (AP1189)
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
-
November 22, 2023 RegulatoryNomination Committee appointed ahead of AGM 2024 in SynAct Pharma AB
-
November 14, 2023 Non RegulatorySynAct Pharma comments on ownership changes in Bioinvest Aps
SynAct Pharma published the Q3 2023 interim report on October 24, 2023.
-
November 24, 2023SynAct Pharma – CEO Torbjørn Bjerke comments on the recent development
-
October 24, 2023Interim Report Q3 2023 – Presentation
A MESSAGE FROM OUR CEO
“We remain optimistic about the prospects of resomelagon in RA and other inflammatory diseases where significant populations of patients are underserved by existing therapies.”